You are here

Levi Garraway

Levi Garraway, M.D., Ph.D.

Levi Garraway is an institute member of the Broad Institute, and is the inaugural director of the Joint Center for Cancer Precision Medicine (CCPM) at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute.

The overall aim of Garraway’s research is to develop systematic approaches to link genomic changes in tumors to novel avenues for targeted cancer treatments. He has made seminal research contributions in cancer genomics and drug resistance. He published the first genome sequencing studies of aggressive primary prostate cancer, and has led major sequencing initiatives in melanoma and head/neck cancers. At the Broad, he also leads the Cancer Cell Line Encyclopedia, a collaboration with Novartis that involves a genomic and pharmacological study of ~1000 human cancer cell lines to characterize sensitivity and resistance to anticancer agents.

Garraway is perhaps best known for his contributions to genomics-driven (or “precision”) cancer medicine. He described the first high-throughput adaptation of a genomic technology to profile human tumors for hundreds of “actionable” cancer gene mutations. This provided a basis for tumor mutation profiling as a means to stratify cancer patients for clinical trial enrollment and, in the future, optimal therapeutic choices. He also demonstrated the promise of massively parallel sequencing as a clinical tumor genomic profiling approach. This research has inspired precision medicine initiatives at many cancer centers worldwide.

In addition to his roles at the Broad, Garraway is an associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School. As Director of CCPM, he leads a cooperative effort between the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute to implement cutting-edge genomic and molecular approaches to oncology clinical trials to direct future therapeutic development and dissect mechanisms of therapeutic resistance.

Garraway has been the recipient of several awards and honors, including the Paul Marks Prize for Cancer Research, the Minority Scholar Award from the American Association of Cancer Research, the Career Award in the Biomedical Sciences from the Burroughs-Wellcome Fund, and the prestigious New Innovator Award from the National Institutes of Health. In 2009, he was inducted into the American Society for Clinical Investigation.

Garraway received his A.B. in biochemical sciences from Harvard College, and his M.D. and Ph.D. from Harvard Medical School. He completed his internship and residency in internal medicine at the Massachusetts General Hospital and his fellowship training in medical oncology at the Dana-Farber Cancer Institute. 

June 2015